COMPANY
AEON Biopharma
AEON’s development program is built around ABP-450 (prabotulinumtoxinA), the same 900 kDa botulinum toxin type A complex that is approved for aesthetic use in the United States, the European Union, and Canada, and approved across a total of 69 countries worldwide for aesthetic and therapeutic indications, including approvals as a biosimilar in multiple international markets. We are developing ABP-450 as a branded biosimilar to Botox®, guided by the FDA’s biosimilar framework. From company website Source · Oct 13, 2026
Timeline
- Raise Follow-on offering: $13.75M (total, as published), announced Jul 13, 2026. Source: SEC filing. source ↗
- Raise Private placement: amount not published, announced Nov 20, 2025. Source: company release on GlobeNewswire. source ↗
- Raise Follow-on offering: $20M (total, as published), announced Jan 7, 2025. Source: SEC filing. source ↗
- Trial start Phase 2: Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention source ↗
- Trial start Phase 2: Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia source ↗
- Trial start 2: A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia source ↗
- Trial start Phase 2: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults source ↗
Funding
- Follow-on offering: $13.75M (total, as published), announced Jul 13, 2026. Source: SEC filing. source ↗
- Private placement: amount not published, announced Nov 20, 2025. Source: company release on GlobeNewswire. source ↗
- Follow-on offering: $20M (total, as published), announced Jan 7, 2025. Source: SEC filing. source ↗
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05016661 | Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention | Phase 2 | Terminated | Oct 19, 2021 | Jul 31, 2024 (actual) |
| NCT04845178 | Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults | Phase 2 | Completed | Mar 1, 2021 | Jun 19, 2024 (actual) |
| NCT04871451 | Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia | Phase 2 | Completed | Jul 27, 2021 | Jul 24, 2023 (actual) |
| NCT04849988 | A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia | 2 | Completed | Mar 29, 2021 | Jul 11, 2022 (actual) |